FirstWord’s Trends and Innovations in Drug Pricing report dissects international trends and examines how long-standing dynamics in competitive pricing and access will strengthen the payer position in demanding discounts in return for guaranteed patient access. Up-to-the-minute and based on the most current research and expert interviews, Trends and Innovations in Drug Pricing is an open window to the future of drug pricing.
Worldwide, the trend towards payers determining price has been firmly entrenched for years. Yet in the US, more aggressive approaches to pricing through exclusive deals that swap discounts for patient access are only now gaining traction.
As arrangements like that which saw Gilead Sciences granted exclusive coverage by CVS Health for the premium priced hepatitis C drugs Harvoni (ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir) increasingly become the norm, the pricing landscape is likely to undergo significant change. And as payers focus is on containing costs and ensuring value for money, what is the takeaway message for pharma?
Read complete article here: